Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
105 hedge funds and large institutions have $161M invested in Aratana Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 32 increasing their positions, 22 reducing their positions, and 14 closing their positions.
180% more call options, than puts
Call options by funds: $123K | Put options by funds: $44K
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
45% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 22
9% more funds holding
Funds holding: 96 → 105 (+9)
17% less capital invested
Capital invested by funds: $194M → $161M (-$33.7M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.8M |
| 2 |
Morgan Stanley
New York
|
+$2.08M |
| 3 |
GAI
General American Investors
New York
|
+$1.53M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.31M |
| 5 |
NSEDCP
NJ State Employees Deferred Compensation Plan
Trenton,
New Jersey
|
+$857K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$5.91M |
| 2 |
BC
Broadfin Capital
New York
|
-$5.45M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.57M |
| 4 |
TAM
Tocqueville Asset Management
New York
|
-$1.58M |
| 5 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$1.06M |
PETX Hedge Fund Activity: Q4 2017 in Review
105 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q4 2017, worth a combined $161M — down 17% from $194M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new PETX positions and 14 closed out — a net gain of 9 holders — while 32 added to existing stakes and 22 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $3.8M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $5.91M sold.
- 105 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q4 2017, up from 96 in Q3 2017.
- Funds reported $161M of Aratana Therapeutics, Inc. stock for Q4 2017, down 17% quarter-over-quarter.
- 23 funds opened new Aratana Therapeutics, Inc. positions in Q4 2017 and 14 closed out, a net change of +9 holders.
- The largest Aratana Therapeutics, Inc. buyer in Q4 2017 was Millennium Management, an estimated $3.8M added.
- The largest Aratana Therapeutics, Inc. seller in Q4 2017 was Alyeska Investment Group, an estimated $5.91M sold.
Based on aggregated 13F filings for Q4 2017.